Skip to main content
Download PDF

Increased unsaturated lipids underlie lipid peroxidation in synucleinopathy brain

Acta Neuropathologica Communications volume 10, Article number: 165 (2022) Cite this article

Abstract

Lipid peroxidation is a process of oxidative degradation of cellular lipids that is increasingly recognized as an important factor in the pathogenesis of neurodegenerative diseases. We were therefore interested in the manifestation of lipid peroxidation in synucleinopathies, a group of neurodegenerative diseases characterized by the central pathology of α-synuclein aggregates, including Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies and Alzheimer’s disease with Lewy bodies. We assessed lipid peroxidation products, lipid aldehydes, in the amygdala, a common disease-affected region in synucleinopathies, and in the visual cortex, a disease-unaffected region. We found that the levels of lipid aldehydes were significantly increased in the amygdala, but not in the visual cortex. We hypothesized that these increases are due to increases in the abundance of unsaturated lipids, since lipid aldehydes are formed from unsaturated lipids. We undertook a comprehensive analysis of membrane lipids using liquid chromatography-mass spectrometry and found that unsaturated phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine and sphingomyelin were specifically elevated in the amygdala and correlated with increases in lipid aldehydes. Furthermore, unsaturated phosphatidylethanolamine levels were associated with soluble α-synuclein. Put together, these results suggest that manifestation of lipid peroxidation is prevalent in synucleinopathies and is likely to be due to increases in unsaturated membrane lipids. Our findings underscore the importance of lipid peroxidation in α-synuclein pathology and in membrane structure maintenance.

Introduction

Synucleinopathies are a group of neurodegenerative diseases that have in common the central pathology of α-synuclein aggregates in the brain with evidence of α-synuclein transmission between cells [37]. Synucleinopathies include Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) with neuronal α-synuclein-positive Lewy pathologies dominating PD and DLB [45], while α-synuclein-positive glial cytoplasmic inclusions dominate MSA [21]. Alzheimer's disease with Lewy bodies (ADLB) is also considered a synucleinopathy, although it is pathologically quite distinct from other synucleinopathies in that α-synuclein aggregates present in ADLB brains are mostly restricted to the amygdala [2, 28].

An important aspect of α-synuclein biology for its oligomerization is its physiochemical interaction with lipids. α-Synuclein normally exists as a natively unfolded monomeric protein within the cytoplasm. However, when it interacts with lipids, such as phospholipid membranes, it undergoes structural changes that results in the formation of insoluble aggregates [13, 27]. It is thought that the amphipathic α-helical motif present in α-synuclein, which is similar to motifs present in lipid-binding proteins (e.g. apolipoproteins), plays a crucial role in the phospholipid binding process [41]. α-Synuclein-lipid binding, and its subsequent oligomerization, is dependent on the composition of membrane phospholipids with preferential binding to regions enriched in sphingolipids, such as sphingomyelin (SM) [5, 11, 20, 27, 32]. It is also dependent on asymmetry of the phospholipid bilayer containing the phospholipids phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS) [12, 18, 29].

The integrity and function of membrane phospholipids are detrimentally affected by lipid peroxidation [34], which is a process of oxidative degradation of lipids caused by reactive oxygen species (ROS) or by via enzymatic routes involving enzymes, such as 15-lipoxygenases and aldehyde dehydrogenases [10, 17]. ROS specifically targets carbon–carbon double bonds in unsaturated fatty acids. The brain is particularly susceptible to ROS due to its high content of unsaturated fatty acids in membranes and high oxygen consumption [44]. Lipid peroxidation causes a direct degradation of membrane phospholipids resulting in membrane dysfunction. It also results in the formation of lipid aldehydes, such as acrolein and malondialdehyde, which are highly reactive and toxic as they bind to cellular proteins and annul their function. Growing evidence indicates that toxic products formed from lipid peroxidation contribute to the pathogenesis of most, if not all, neurodegenerative diseases, as well as occurring in normal ageing [36, 39].

Here, we investigated manifestation of lipid peroxidation across multiple synucleinopathies, namely PD, DLB, MSA and ADLB. Specifically, we measured lipid aldehydes, acrolein and malondialdehyde in the common disease-affected region amygdala. We also investigated the possible cause of the elevation of lipid aldehydes in synucleinopathies by analyzing the abundance of unsaturated PC, PE, PS and SM in the amygdala.

Materials and methods

Human brain tissues

Frozen post-mortem brain tissue samples were obtained from Sydney Brain Bank and NSW Brain Tissue Resource Centre. Ethical approvals were acquired from the human research ethics committees of University of New South Wales (approval number: HC16568) and the University of Sydney (approval number: 2020/707). Frozen samples from the amygdala and the visual cortex from 8 PD, 5 DLB, 8 MSA and 7 ADLB cases and 10 controls without neurological, psychiatric or neuropathological diagnoses were used in this study (Additional file 1: Table S1).

Chemicals and materials

Lipids were extracted using chloroform or methyl-t-butyl ether, methanol and isopropanol (Sigma Aldrich, St. Louis, MO, USA) and ultrapure water (Millipore). All solvents used were HPLC grade or higher. Glass pipettes and tubes were used wherever possible and the use of plasticware was minimized during lipid extraction to avoid contamination of samples. Glass tubes and glass transfer pipettes were purchased from Sigma and VWR. Lipid internal standards (ISTDs) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). These include phosphatidylcholine (19:0), sphingomyelin (12:0), phosphatidylethanolamine (17:0), phosphatidylglycerol (17:0), phosphatidylserine (17:0), phosphatidic acid (17:0), ceramide (d18:1, 12:0), diglyceride (1,3 18:0 d5), cholesteryl ester (19:0), monoglyceride (17:0), triglyceride mix d5 (Avanti Code LM-6000), diglyceride mix d5 (Avanti Code LM-6001), phosphatidylinositol (17:0 14:1), C12 GluCer, C12 sulfatide, C17 ceramide, C17 sphingosine, C17 S1P, C12 C1P, D3 C20 fatty acid, and C12 LacCer. Lipid internal standards were prepared as a mixture at 10 pmol/µl in methyl-tert butyl ether and methanol (MTBE:methanol, 1:1 v/v).

Immunohistochemistry

Formalin-fixed paraffin-embedded sections were deparaffinized with xylene and then rehydrated with gradient ethanol and water. Antigen retrieval was conducted with 70% formic acid followed by heating in a pressure cooker (Aptum Bio Retriever 2100, Aptum Biologics Ltd, UK). Endogenous peroxidase activity was quenched with 1% H2O2 in 50% ethanol for 30 min and then washed in distilled water. Sections were further blocked with 5% normal horse serum prior to incubation in medium containing primary antibody phospho-S129 (Abcam Ab51253, 1:500) or O2 (Creativebiolab TAB-0748CLV, 1:200) at 4 °C for 2 days. Sections were washed and incubated with either alkaline phosphatase (AP)-anti-mouse or horseradish peroxidase (HRP)-anti-rabbit secondary polymer antibodies (VECTOR, ImmPRESS, cat.# MP-5402 & MP-7401). The immunoreactive color was developed with ImmPACT Vector Red AP Substrate (VECTOR, SK-5105) or ImmPACT DAB EqV Peroxidase (HRP) Substrate (VECTOR, SK-4103) respectively, prior to counterstaining with hematoxylin. Sections were then dehydrated with gradient ethanol and cleared with xylene prior to coverslipping with D.P.X. Images were obtained at × 20 magnification using an Olympus slide scanner (VS120).

Protein extraction

Tris-buffered saline (TBS) and SDS-soluble proteins were serially extracted from 100 mg of fresh-frozen brain tissues, as previously described [31]. Briefly, tissues were homogenized in ten volumes of TBS homogenization buffer (20 mM Tris, 150 mM NaCl, pH 7.4, 5 mM EDTA, 0.02% sodium azide) containing protease inhibitor cocktail (Roche) using Qiagen TissueLyser (3 × 30 s, 30 Hz cycles), followed by centrifugation at 100,000 g for 1 h at 4 °C, with supernatant collected as TBS-soluble fraction. The pellet was resuspended in SDS solubilization buffer (TBS homogenization buffer containing 5% SDS) using 3 × 30 s, 30 Hz cycles with TissueLyser, and centrifuged at 100,000 g for 30 min at 25 °C, with supernatant collected as SDS-soluble fraction. Protein concentration was measured using a bicinchoninic acid assay (Pierce BCA Protein Assay Kit) following the manufacturer’s instructions.

Western blotting and ELISA

Protein lysates (10 µg) were heated with sample buffer (3.2% SDS, 32% glycerol, 0.16% bromophenol blue, 100 mM Tris–HCl, pH 6.8, 8% 2-mercaptoethanol). They were then electrophoresed on Criterion Stain-free 4–20% SDS-PAGE gels (Bio-Rad) and transferred onto nitrocellulose membranes at 100 V for 30 min. The membranes were blocked with TBS containing 5% nonfat dry milk and probed with α-synuclein antibody (1:1000, BD Biosciences, 610,787), NFL antibody (1:2000, Cell Signaling, 2835S) or acrolein antibody (1:1000, NOVUS, NB200-556) overnight at 4 °C. They were then washed three times in TBS containing 0.1% Tween 20 and incubated with horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. Signals were detected using enhanced chemiluminescence and Gel Doc System (Bio-Rad). The blots were stripped and probed for housekeeper proteins tubulin or GAPDH. The signal intensity was quantified using Image Lab (Bio-Rad) and NIH ImageJ software (v1.45 s). ELISA of α-synuclein (Legend Max Cat no: 844101) was carried out following the manufacturer’s protocol. ELISA of neurofilament light (Novus Cat no: NBP2-81,184) was carried out following the manufacturer’s protocol.

RNA extraction and quantitative PCR

RNA was isolated using TRIzol reagent (Invitrogen) following the manufacturer’s protocol as previously described [36]. All procedures were carried out using RNase-free reagents and consumables. One microgram of RNA was reverse transcribed into cDNA using Moloney-murine leukemia virus (M-MLV) reverse transcriptase and random primers (Promega, Madison, Wisconsin, USA) in 20 μl reaction volume. Quantitative PCR (qPCR) assays were carried out using a Mastercycler ep realplex S (Eppendorf, Sydney, Australia) and the fluorescent dye SYBR Green (Bio-Rad), following the manufacturer’s protocol. Briefly, each reaction (20 μl) contained 1 × mastermix, 5 pmol of primers and 1 μl of cDNA template. Amplification was carried out with 40 cycles of 94 °C for 15 s and 60 °C for 1 min. Gene expression was normalized to the geometric mean of three housekeeper genes, GAPDH, β-actin and PPIA. A no-template control was included for each PCR amplification assay. The level of expression for each gene was calculated using the comparative threshold cycle (Ct) value method using the formula 2−ΔΔCt (where ΔΔCt = ΔCt sample – ΔCt reference).

Malondialdehyde assay

Malondialdehyde was measured using Lipid Peroxidation MDA Assay Kit (Abcam, cat. # ab118970) following the manufacturer’s protocol. Briefly, TBA solution was added into each vial containing samples or standards and incubated at 95 °C for 1 h. Signal at 532 nm was read using CLARIOstar plate reader (BMG Labtech).

Lipid extraction

Brain tissue lipid extraction was based on the Matyash method [30]. Briefly, 10 mg of fresh-frozen brain tissues were homogenized in methanol containing 0.01% BHT (300 µl) using a Qiagen TissueLyser (3 × 30 s, 30 Hz cycles). The homogenates were transferred to glass tubes, as well as the methanol (430 µl) wash of the beads. MTBE (2.42 ml) was added and the mixture vortexed and incubated for 30 min at room temperature. Water (600 µl) was added and the mixture vortexed and centrifuged at 1000 g for 10 min. The upper phase was transferred to a new glass tube using a glass Pasteur pipette. The lower phase was re-extracted using MTBE/MeOH/water (10:3:2.5). The preparation was dried under nitrogen gas. Dried lipid samples were reconstituted in 100 µl of chloroform/methanol (1:1) and stored at − 80℃.

Liquid chromatography—mass spectrometry

Lipid extracts (10 μl) were analyzed using a Q-Exactive Plus Mass Spectrometer coupled to a U3000 UPLC system (ThermoFisher Scientific). Chromatography was performed at 60℃ on a Waters CSH C18 UHPLC column 2.1 × 100 mm, 1.8 μM with VanGuard guard column. Solvent A was 6:4 acetonitrile:water and Solvent B was 1:9 acetonitrile:isopropanol, both with 10 mM ammonium formate and 0.1% formic acid. Lipids were chromatographed according to the method of Castro-Perez et al. [8]. Briefly, a 30 min gradient running from 30 to 100% of solvent B was performed, eluting lipids in order of hydrophobicity. Column eluate was directed into the electrospray ionization source of the mass spectrometer where a HESI probe was employed. Source parameters were broadly optimized on a range of lipid standards prior to the analysis. The mass spectrometer was run in data dependent acquisition mode. A survey scan over the mass range 200–1200 at resolution 70 K was followed by 10 data dependent MS/MS scans on the most intense ions in the survey at 15 K resolution. Dynamic exclusion was used to improve the number of ions targeted. Cycle time was approximately 1 s. Samples were run in both positive and negative polarities. The samples were run in a random order (generated using Microsoft Excel). This is important to avoid batch effects/changing instrument performance effects. Data were analysed in LipidSearch software 4.1.16. Data were searched against the standard Lipidsearch database with all common mammalian lipid classes included. The search results were then grouped according to sample type and aligned for differential analysis. Aligned data (containing lipid identity, retention time, peak area etc.) were exported to Excel software. Relative abundance of lipids was obtained from peak areas normalized to internal standards.

Statistical analysis

Statistical analyses were performed using SPSS Statistics software (IBM, Chicago, Illinois) as previously described [36]. Multivariate analyses (general linear model) covarying for age and sex were used to determine differences in lipid levels in the synucleinopathies and control groups with posthoc statistical significance set at p < 0.05. Pearson’s correlations were used to determine if changes in measurements were associated with each other with statistical significance set at p < 0.05. Graphs were generated using GraphPad Prism 9.

Results

Verification of synucleinopathies

Lipid peroxidation is increasingly recognized as a significant contributing factor in the pathogenesis of neurodegenerative diseases. We were therefore interested in the manifestation of lipid peroxidation across synucleinopathies (PD, DLB, MSA and ADLB). Firstly, we confirmed the presence of α-synuclein pathology in these synucleinopathies by immunostaining (Fig. 1a) and by western blotting of the amygdala (Fig. 1b). As a gauge of neurodegeneration, we measured neurofilament light (NFL) in the same tissues by western blotting (Fig. 1c) and ELISA (Additional file 1: Fig. S1), and found that it was unaltered in the synucleinopathies compared controls, suggesting that the neuronal integrity of these tissues was still intact. We also showed that α-synuclein mRNA expression in the synucleinopathies was unaltered in the amygdala (Fig. 1d), indicating that α-synuclein aggregates present in the synucleinopathies was due to increased α-synuclein accumulation rather than increased α-synuclein production.

Fig. 1
figure 1

Presence of α-synuclein pathology in synucleinopathies. a Representative images of immunohistochemistry of α-synuclein aggregates (arrowed) in the amygdala of Parkinson’s disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB) and Alzheimer’s disease with Lewy bodies (ADLB) and absent in controls (Con); scale bars = 50 µm. b Western blotting of insoluble fraction of α-synuclein in the amygdala and optical density (OD) measurement of the protein bands normalized to β-tubulin. c Western blotting of neurofilament light (NFL) in the amygdala and OD measurement of the protein bands normalized to GAPDH. d mRNA expression of α-synuclein in the amygdala. Data represent mean and SE as error bars, *P < 0.05

Full size image

Increases in lipid aldehydes in synucleinopathies

Lipid peroxidation results in the formation of lipid aldehydes, and the major lipid aldehydes in the brain are acrolein and malondialdehyde (MDA). Acrolein and MDA are highly reactive and readily form conjugates with cellular proteins, annulling their function, and therefore are indirect indicators of lipid peroxidation. To assess the degree of lipid peroxidation, we measured acrolein-conjugated proteins by western blotting, and MDA levels, by colorimetric assay, in the amygdala. We also measured the two aldehydes in the visual cortex, which is largely unaffected in synucleinopathies and can be considered as an unaffected control region. We found significant increases in acrolein-conjugated proteins in the amygdala in all four synucleinopathies (Fig. 2a), but no significant changes were observed in the visual cortex (Fig. 2b). MDA levels in the amygdala were also significantly increased in PD, MSA and ADLB with non-significant increases in DLB (Fig. 2c). Again there were no significant changes in the visual cortex (Fig. 2d). These results suggest that lipid peroxidation occurs in the brain of synucleinopathies in a region-specific manner.

Fig. 2
figure 2

Analysis of lipid peroxidation in synucleinopathies. Western blotting of acrolein-conjugated proteins in the amygdala (a) and the visual cortex (b), and optical density (OD) measurement of the protein bands normalized to GAPDH. A colorimetric measurement of malondialdehyde (MDA) in the amygdala (c) and the visual cortex (d). Data represent mean and SE as error bars, *P < 0.05

Full size image

Increases in unsaturated lipids in synucleinopathies

Since lipid aldehydes are formed from unsaturated lipids, we hypothesized that increases in lipid aldehydes in synucleinopathies are due to increases in the abundance of unsaturated lipids. Unsaturated lipids contain fatty acids with one or more carbon–carbon double bonds and these bonds are the site for the peroxidation reaction. Therefore, the greater the abundance of unsaturated lipids the greater the susceptibility to lipid peroxidation. We undertook a comprehensive analysis of lipids in the amygdala and visual cortex using liquid chromatography-mass spectrometry and the LipidSearch software. The statistics were performed using SPSS Statistics software in the multivariate analysis (general linear model) mode covarying for age and sex. We assessed four major membrane lipid classes, phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and sphingomyelin (SM) in each of the synucleinopathies and found elevated levels of unsaturated PC in MSA and ADLB, unsaturated PE in MSA, unsaturated PS in PD and ADLB, and unsaturated SM in MSA and DLB in the amygdala (Fig. 3a). Notably, three of the four unsaturated lipids were elevated in MSA amygdala. In contrast, none of the unsaturated lipids were elevated in the visual cortex in any of the synucleinopathies (Fig. 3b). To further understand the changes in unsaturated lipids in the amygdala, we examined lipid species and found that they were strongly correlated with one another in each of the classes (Fig. 3c), suggesting that the elevation of unsaturated lipids was universal. Importantly, specific unsaturated lipid species were correlated to MDA and acrolein levels in the amygdala (Fig. 3d).

Fig. 3
figure 3

Measurement of unsaturated lipids in synucleinopathies using liquid chromatography-mass spectrometry. a Abundance (Abd) of unsaturated phosphatidylcholine (PC), unsaturated phosphatidylethanolamine (PE), unsaturated phosphatidylserine (PS) and unsaturated sphingomyelin (SM) in the amygdala; data represent mean and SE as error bars, *P < 0.05, **P < 0.01, ***P < 0.005. b Abundance of unsaturated lipids in the visual cortex. c Pearson’s correlation of unsaturated lipid species within each lipid class. d Pearson’s correlation of unsaturated lipid species with malondialdehyde (MDA) and acrolein levels in the amygdala

Full size image

Correlation between unsaturated PE and soluble α-synuclein

To further understand the effect of unsaturated lipids in synucleinopathies, we assessed the relationship between unsaturated lipids and α-synuclein, the major pathogenic protein in synucleinopathies. We measured soluble α-synuclein in the amygdala by ELISA and found no significant changes in any of the synucleinopathies compared to controls (Fig. 4a), which is consistent with the α-synuclein mRNA expression results (Fig. 1d). α-Synuclein levels, however, were significantly correlated to unsaturated PE species (Fig. 4b) and to the total unsaturated PE class (Fig. 4c). No significant correlation was observed between α-synuclein levels and the other lipid classes (Additional file 1: Fig. S2).

Fig. 4
figure 4

Soluble α-synuclein is associated with unsaturated phosphatidylethanolamine (PE). a ELISA measurement of soluble α-synuclein in the amygdala; data represent mean and SE as error bars. Pearson’s correlation of soluble α-synuclein with b unsaturated PE species and c the total unsaturated PE class in the amygdala

Full size image

Discussion

In the current study we investigated manifestation of lipid peroxidation in the brain of synucleinopathies that include PD, DLB, MSA and ADLB. We demonstrated that lipid aldehydes, acrolein and MDA, were elevated across synucleinopathies, specifically in the common disease-affected region, amygdala (Fig. 2), and that these increases were associated with increases in specific unsaturated lipids (Fig. 3). Unsaturated lipids of at least one lipid class (PC, PE, PS or SM) were elevated in the amygdala of each of the synucleinopathies, with three lipid classes elevated in MSA.

Consistent with our findings, other lipid aldehydes have been shown to be elevated in the brain of neurodegenerative diseases in a region-specific manner. For example, lipid aldehydes 4-hydroxy-2-nonenal (HNE) and 4-oxo-2-nonenal (ONE) are elevated in the substantia nigra of PD brain [16], particularly in the nigral neurons [51]. Again, HNE levels are elevated in the frontal cortex, but not in the cerebellum, of Alzheimer’s disease (AD) [40]. Interestingly, MDA, the lipid aldehyde that was elevated in PD, MSA and ADLB (Fig. 2c), has been shown to form deposits associated with lipofuscin in AD hippocampal neurons, particularly in the CA4 region [15]. MDA also colocalizes with senile plaques and neurofibrillary tangles in AD [15].

We observed increases in the abundance of unsaturated lipids with various fatty acid chain length and number of carbon–carbon double bonds, including fatty acids with 22 carbon atoms and 6 double bonds (22:6). Typically, numerous numbers of different lipid species are present in brain tissues, however the function of most of these brain lipid species is unknown. One unsaturated fatty acid that is of interest in the context of neurodegeneration is docosahexaenoic acid (DHA; 22:6) [4]. The brain is particularly enriched in DHA [9], and increases in DHA levels in PD and DLB brain are thought to contribute to the oligomerization of α-synuclein and subsequent neuronal damage [43]. The detrimental impact of increases in DHA levels is supported by the fact that DHA can form covalent bonds with α-synuclein [14]. The interaction of HNE, one of main products of DHA peroxidation, with α-synuclein has been shown to promote the formation of toxic α-synuclein oligomers [38, 42]. ONE has also been shown to promote the oligomerization of monomeric α-synuclein [6, 33], and enhance the stability and yield of α-synuclein oligomers [1]. Consistent with these findings, increases in unsaturated lipids are associated with increases in α-synuclein toxicity in neurons [19]. Furthermore, when unsaturated lipids are reduced by an inhibition of stearoyl-CoA desaturase (enzyme that converts saturated fatty acids into unsaturated fatty acids), α-synuclein toxicity in human-derived neurons is reduced [47].

Under pathological conditions, such as in synucleinopathies, α-synuclein is known to undergo conformational changes that enhances the formation of oligomers. This process is thought to be initiated when α-synuclein binds and interacts with lipid membranes. In vitro studies showed that α-synuclein monomers, isolated from primary neurons, readily bound to lipid membranes and formed oligomers [13, 27]. An amphipathic α-helical motif present in α-synuclein, similar to those present in lipid-binding proteins, is thought to facilitate the lipid membrane binding process [41]. The binding/interaction of α-synuclein to membranes and subsequent oligomerization is also dependent on the lipid composition of membranes [11, 22, 27] with preferential binding to regions of membranes that are enriched in sphingolipids [20].

We found that unsaturated PE levels were strongly correlated with soluble α-synuclein in the amygdala. This is an interesting result in light of the observation that α-synuclein accumulation is modulated by cellular PE levels [48]. In yeast and worm models of PD, decreases in the level of total PE (not unsaturated PE) resulted in increased accumulation of α-synuclein foci resembling α-synuclein deposits [48]. The role of PE is particularly important in the brain as it makes up ~ 45% of brain phospholipids [46]. A study using magnetic resonance spectroscopic imaging showed that the level of total PE (not unsaturated PE) in the putamen was decreased in brains of early (Hoehn and Yahr stages I/II) PD patients, but not in advanced (Hoehn and Yahr stages III/IV) PD patients [24]. In another study, the presence of PE in phospholipid vesicles significantly augmented the binding of soluble α-synuclein to the membrane and resulted in extensive bilayer disruption and the formation of fibrils [25]. These and other studies that implicate PE in α-synuclein pathology, however, do not stipulate whether the lipids are saturated or unsaturated, nor the identity of the lipid species involved, and therefore comparative analyses of results from different studies are difficult.

MSA had the greatest and most significant increase in unsaturated lipids out of the four synucleinopathies. MSA is the most rapidly developing and devastating disease with a broader distribution of α-synuclein pathology compared to the other three synucleinopathies [35, 49]. Another key difference between MSA and the other three synucleinopathies is that the principal cell type involved is oligodendrocytes rather than neurons. Oligodendrocytes contain the specialized membranous myelin, which is highly enriched in unsaturated lipids, and therefore susceptible to greater lipid peroxidation. Future studies could investigate the degree of lipid peroxidation in oligodendrocytes compared to neurons and their toxic effect in these two cell types in MSA. Interestingly, in multiple sclerosis, which is a chronic inflammatory disease affecting oligodendrocytes, the levels of MDA and other lipid aldehydes are increased in oligodendrocytes [23].

We observed that unsaturated PS levels were elevated in the amygdala of PD and ADLB. PS is an integral membrane phospholipid that allows asymmetrical membrane curvature. Normally, PS is sequestered to the inner leaflet of the lipid bilayer (cytosolic) in an asymmetric manner. However, lipid peroxidation of PS causes changes to the membrane structure by a redistribution of PS in the membrane. Collapse of lipid asymmetry and exposure of PS on the cell surface initiates a number of pathological changes. One such change is the initiation of early apoptotic events and consequent phagocytosis of targeted cells [50]. Lipid peroxidation of PS has been shown to be important for PS egression to the cell surface in apoptotic cells [26]. Furthermore, exposure of PS to the cell surface altered the activity of proteins embedded in membranes, such as receptors and transporters [3]. In AD brain, the lipid aldehyde acrolein altered the asymmetric distribution of PS in the membrane [7].

In summary, we have revealed that lipid peroxidation is prevalent in synucleinopathies and that increased levels of lipid aldehydes are likely to be due to increased levels of unsaturated lipids in membranes. These changes were however observed in postmortem tissues, i.e. late stages of disease, and therefore could be possibly compensatory effects, rather than pathogenic impact, although the NFL levels were not altered in the synucleinopathies compared controls, suggesting that the neuronal integrity of these tissues was still intact. Nevertheless, our findings underscore the importance of lipid peroxidation in α-synuclein pathology and in the maintenance of membrane structure and cellular homeostasis.

Data availability

Lipidomics raw data were generated at Bioanalytical Mass Spectrometry Facility, University of New South Wales. Derived data supporting the findings of this study are available from the corresponding author, upon reasonable request. Other patient data cannot be made publicly available because the ethical approval and the informed consent from the patients included in this study did not cover placing the data into publicly open repositories.

References

  1. Andersen C, Gronnemose AL, Pedersen JN, Nowak JS, Christiansen G, Nielsen J, Mulder FAA, Otzen DE, Jorgensen TJD (2021) Lipid peroxidation products HNE and ONE promote and stabilize alpha-synuclein oligomers by chemical modifications. Biochemistry 60:3644–3658. https://doi.org/10.1021/acs.biochem.1c00478

    Article  CAS  PubMed  Google Scholar 

  2. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) Alpha-synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation. Brain Res 888:287–296

    Article  CAS  PubMed  Google Scholar 

  3. Balasubramanian K, Schroit AJ (2003) Aminophospholipid asymmetry: A matter of life and death. Annu Rev Physiol 65:701–734. https://doi.org/10.1146/annurev.physiol.65.092101.142459

    Article  CAS  PubMed  Google Scholar 

  4. Bazinet RP, Laye S (2014) Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 15:771–785. https://doi.org/10.1038/nrn3820

    Article  CAS  PubMed  Google Scholar 

  5. Bell R, Vendruscolo M (2021) Modulation of the Interactions Between alpha-Synuclein and Lipid Membranes by Post-translational Modifications. Front Neurol 12:661117. https://doi.org/10.3389/fneur.2021.661117

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cai Y, Lendel C, Osterlund L, Kasrayan A, Lannfelt L, Ingelsson M, Nikolajeff F, Karlsson M, Bergstrom J (2015) Changes in secondary structure of alpha-synuclein during oligomerization induced by reactive aldehydes. Biochem Biophys Res Commun 464:336–341. https://doi.org/10.1016/j.bbrc.2015.06.154

    Article  CAS  PubMed  Google Scholar 

  7. Castegna A, Lauderback CM, Mohmmad-Abdul H, Butterfield DA (2004) Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer’s disease. Brain Res 1004:193–197. https://doi.org/10.1016/j.brainres.2004.01.036

    Article  CAS  PubMed  Google Scholar 

  8. Castro-Perez JM, Kamphorst J, DeGroot J, Lafeber F, Goshawk J, Yu K, Shockcor JP, Vreeken RJ, Hankemeier T (2010) Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J Proteome Res 9:2377–2389. https://doi.org/10.1021/pr901094j

    Article  CAS  PubMed  Google Scholar 

  9. Chen CT, Green JT, Orr SK, Bazinet RP (2008) Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids 79:85–91. https://doi.org/10.1016/j.plefa.2008.09.003

    Article  CAS  PubMed  Google Scholar 

  10. Chen Q, Chen Y, Zhang Y, Wang F, Yu H, Zhang C, Jiang Z, Luo W (2019) Iron deposition in Parkinson’s disease by quantitative susceptibility mapping. BMC Neurosci 20:23. https://doi.org/10.1186/s12868-019-0505-9

    Article  PubMed  PubMed Central  Google Scholar 

  11. Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL (2002) Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein. J Biol Chem 277:6344–6352. https://doi.org/10.1074/jbc.M108414200

    Article  CAS  PubMed  Google Scholar 

  12. Dasari AKR, Dillard L, Yi S, Viverette E, Hojjatian A, Sengupta U, Kayed R, Taylor KA, Borgnia MJ, Lim KH (2022) Untwisted alpha-synuclein filaments formed in the presence of lipid vesicles. Biochemistry 61:1766–1773. https://doi.org/10.1021/acs.biochem.2c00283

    Article  CAS  PubMed  Google Scholar 

  13. Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443–9449

    Article  CAS  PubMed  Google Scholar 

  14. De Franceschi G, Fecchio C, Sharon R, Schapira AHV, Proukakis C, Bellotti V, de Laureto PP (2017) alpha-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. J Biol Chem 292:6927–6937. https://doi.org/10.1074/jbc.M116.765149

    Article  PubMed  PubMed Central  Google Scholar 

  15. Dei R, Takeda A, Niwa H, Li M, Nakagomi Y, Watanabe M, Inagaki T, Washimi Y, Yasuda Y, Horie K et al (2002) Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer’s disease. Acta Neuropathol 104:113–122. https://doi.org/10.1007/s00401-002-0523-y

    Article  CAS  PubMed  Google Scholar 

  16. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389. https://doi.org/10.1111/j.1471-4159.1989.tb09133.x

    Article  CAS  PubMed  Google Scholar 

  17. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased Nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52:1830–1836. https://doi.org/10.1111/j.1471-4159.1989.tb07264.x

    Article  CAS  PubMed  Google Scholar 

  18. Dou T, Kurouski D (2022) Phosphatidylcholine and phosphatidylserine uniquely modify the secondary structure of alpha-synuclein oligomers formed in their presence at the early stages of protein aggregation. ACS Chem Neurosci 13:2380–2385. https://doi.org/10.1021/acschemneuro.2c00355

    Article  CAS  PubMed  Google Scholar 

  19. Fanning S, Haque A, Imberdis T, Baru V, Barrasa MI, Nuber S, Termine D, Ramalingam N, Ho GPH, Noble T et al (2019) Lipidomic analysis of alpha-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for parkinson treatment. Mol Cell 73(1001–1014):e1008. https://doi.org/10.1016/j.molcel.2018.11.028

    Article  CAS  Google Scholar 

  20. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 24:6715–6723. https://doi.org/10.1523/JNEUROSCI.1594-04.2004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gai WP, Power JH, Blumbergs PC, Blessing WW (1998) Multiple-system atrophy: a new alpha-synuclein disease? Lancet 352:547–548

    Article  CAS  PubMed  Google Scholar 

  22. Gilmozzi V, Gentile G, Castelo Rueda MP, Hicks AA, Pramstaller PP, Zanon A, Levesque M, Pichler I (2020) Interaction of alpha-synuclein with lipids: mitochondrial cardiolipin as a critical player in the pathogenesis of parkinson’s disease. Front Neurosci 14:578993. https://doi.org/10.3389/fnins.2020.578993

    Article  PubMed  PubMed Central  Google Scholar 

  23. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H (2011) Oxidative damage in multiple sclerosis lesions. Brain 134:1914–1924. https://doi.org/10.1093/brain/awr128

    Article  PubMed  PubMed Central  Google Scholar 

  24. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, Hilker R (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease. Brain 132:3285–3297. https://doi.org/10.1093/brain/awp293

    Article  PubMed  Google Scholar 

  25. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE (2000) alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 275:34328–34334. https://doi.org/10.1074/jbc.M004345200

    Article  CAS  PubMed  Google Scholar 

  26. Kagan VE, Borisenko GG, Serinkan BF, Tyurina YY, Tyurin VA, Jiang J, Liu SX, Shvedova AA, Fabisiak JP, Uthaisang W et al (2003) Appetizing rancidity of apoptotic cells for macrophages: oxidation, externalization, and recognition of phosphatidylserine. Am J Physiol Lung Cell Mol Physiol 285:L1-17. https://doi.org/10.1152/ajplung.00365.2002

    Article  CAS  PubMed  Google Scholar 

  27. Leng Y, Chase TN, Bennett MC (2001) Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J Biol Chem 276:28212–28218. https://doi.org/10.1074/jbc.M011121200

    Article  CAS  PubMed  Google Scholar 

  28. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O’Connell B, Pollen DA, St George-Hyslop P et al (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365–1370

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Mahoney-Sanchez L, Bouchaoui H, Boussaad I, Jonneaux A, Timmerman K, Berdeaux O, Ayton S, Kruger R, Duce JA, Devos D et al (2022) Alpha synuclein determines ferroptosis sensitivity in dopaminergic neurons via modulation of ether-phospholipid membrane composition. Cell Rep 40:111231. https://doi.org/10.1016/j.celrep.2022.111231

    Article  CAS  PubMed  Google Scholar 

  30. Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D (2008) Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res 49:1137–1146. https://doi.org/10.1194/jlr.D700041-JLR200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 1:11. https://doi.org/10.1186/2051-5960-1-11

    Article  PubMed  PubMed Central  Google Scholar 

  32. Musteikyte G, Jayaram AK, Xu CK, Vendruscolo M, Krainer G, Knowles TPJ (2021) Interactions of alpha-synuclein oligomers with lipid membranes. Biochim Biophys Acta Biomembr 1863:183536. https://doi.org/10.1016/j.bbamem.2020.183536

    Article  CAS  PubMed  Google Scholar 

  33. Nasstrom T, Fagerqvist T, Barbu M, Karlsson M, Nikolajeff F, Kasrayan A, Ekberg M, Lannfelt L, Ingelsson M, Bergstrom J (2011) The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic Biol Med 50:428–437. https://doi.org/10.1016/j.freeradbiomed.2010.11.027

    Article  CAS  PubMed  Google Scholar 

  34. Negre-Salvayre A, Coatrieux C, Ingueneau C, Salvayre R (2008) Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 153:6–20. https://doi.org/10.1038/sj.bjp.0707395

    Article  CAS  PubMed  Google Scholar 

  35. Ozawa T, Okuizumi K, Ikeuchi T, Wakabayashi K, Takahashi H, Tsuji S (2001) Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol 102:188–190

    Article  CAS  PubMed  Google Scholar 

  36. Phan K, He Y, Pickford R, Bhatia S, Katzeff JS, Hodges JR, Piguet O, Halliday GM, Kim WS (2020) Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. Sci Rep 10:3640. https://doi.org/10.1038/s41598-020-60457-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN et al (2015) Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 112:E5308-5317. https://doi.org/10.1073/pnas.1514475112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL (2007) Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem 282:5862–5870. https://doi.org/10.1074/jbc.M608126200

    Article  CAS  PubMed  Google Scholar 

  39. Reed TT (2011) Lipid peroxidation and neurodegenerative disease. Free Radic Biol Med 51:1302–1319. https://doi.org/10.1016/j.freeradbiomed.2011.06.027

    Article  CAS  PubMed  Google Scholar 

  40. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease. J Neurochem 68:2092–2097. https://doi.org/10.1046/j.1471-4159.1997.68052092.x

    Article  CAS  PubMed  Google Scholar 

  41. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM (1992) The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 33:141–166

    Article  CAS  PubMed  Google Scholar 

  42. Shamoto-Nagai M, Hisaka S, Naoi M, Maruyama W (2018) Modification of alpha-synuclein by lipid peroxidation products derived from polyunsaturated fatty acids promotes toxic oligomerization: its relevance to Parkinson disease. J Clin Biochem Nutr 62:207–212. https://doi.org/10.3164/jcbn.18-25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, Selkoe DJ (2003) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem 278:49874–49881. https://doi.org/10.1074/jbc.M309127200

    Article  CAS  PubMed  Google Scholar 

  44. Singh M, Dang TN, Arseneault M, Ramassamy C (2010) Role of by-products of lipid oxidation in Alzheimer’s disease brain: a focus on acrolein. J Alzheimer’s Disease 21:741–756. https://doi.org/10.3233/JAD-2010-100405

    Article  CAS  Google Scholar 

  45. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. https://doi.org/10.1038/42166

    Article  CAS  PubMed  Google Scholar 

  46. Vance JE (2008) Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 49:1377–1387. https://doi.org/10.1194/jlr.R700020-JLR200

    Article  CAS  PubMed  Google Scholar 

  47. Vincent BM, Tardiff DF, Piotrowski JS, Aron R, Lucas MC, Chung CY, Bacherman H, Chen Y, Pires M, Subramaniam R et al (2018) Inhibiting Stearoyl-CoA desaturase ameliorates alpha-synuclein cytotoxicity. Cell Rep 25(2742–2754):e2731. https://doi.org/10.1016/j.celrep.2018.11.028

    Article  CAS  Google Scholar 

  48. Wang S, Zhang S, Liou LC, Ren Q, Zhang Z, Caldwell GA, Caldwell KA, Witt SN (2014) Phosphatidylethanolamine deficiency disrupts alpha-synuclein homeostasis in yeast and worm models of Parkinson disease. Proc Natl Acad Sci U S A 111:E3976-3985. https://doi.org/10.1073/pnas.1411694111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Wenning G, Tison F, Ben Shlomo Y, Daniel S, Quinn N (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12:133–147

    Article  CAS  PubMed  Google Scholar 

  50. Williamson P, Schlegel RA (2002) Transbilayer phospholipid movement and the clearance of apoptotic cells. Biochim Biophys Acta 1585:53–63. https://doi.org/10.1016/s1388-1981(02)00324-4

    Article  CAS  PubMed  Google Scholar 

  51. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93:2696–2701. https://doi.org/10.1073/pnas.93.7.2696

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by funding from Defeat MSA Alliance. G.M.H. is a NHMRC Senior Leadership Fellow (#1176607). Tissues were received from the New South Wales Brain Tissue Resource Centre at the University of Sydney and the Sydney Brain Bank at Neuroscience Research Australia, which are supported by The University of New South Wales, Neuroscience Research Australia and Schizophrenia Research Institute. Research reported in this publication was supported by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number R28AA012725. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We also acknowledge the facilities and the scientific and technical assistance of Microscopy Australia at the Australian Centre for Microscopy & Microanalysis at the University of Sydney.

Author information

Author notes

  1. YuHong Fu and Ying He have contributed equally to this work

Authors and Affiliations

  1. Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia

    YuHong Fu, Ying He, Katherine Phan, Surabhi Bhatia, Ping Wu, Nicolas Dzamko, Glenda M. Halliday & Woojin Scott Kim

  2. School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia

    YuHong Fu, Ying He, Katherine Phan, Surabhi Bhatia, Ping Wu, Nicolas Dzamko, Glenda M. Halliday & Woojin Scott Kim

  3. Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, NSW, Australia

    Russell Pickford

  4. School of Medical Sciences, University of New South Wales & Neuroscience Research Australia, Sydney, NSW, Australia

    Glenda M. Halliday & Woojin Scott Kim

Authors
  1. YuHong Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katherine Phan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Surabhi Bhatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Russell Pickford
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ping Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicolas Dzamko
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Glenda M. Halliday
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Woojin Scott Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

W.S.K. conceived, developed and supervised the project, analyzed the data, and wrote the manuscript. Y.F. carried out immunohistochemical analysis, provided expert advice and revised the manuscript. G.M.H. and N.D. provided expert advice and revised the manuscript. Y.H., K.P. and P.W. carried out western blotting, qPCR and other biochemical assays. S.B. and R.P. carried out HPLC–MS and lipidomics analysis.

Corresponding author

Correspondence to Woojin Scott Kim.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Synucleinopathy brain data.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fu, Y., He, Y., Phan, K. et al. Increased unsaturated lipids underlie lipid peroxidation in synucleinopathy brain. acta neuropathol commun 10, 165 (2022). https://doi.org/10.1186/s40478-022-01469-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40478-022-01469-7

Keywords

  • Lipid peroxidation
  • Synucleinopathies
  • Parkinson’s disease
  • Lipid aldehydes
  • Unsaturated lipids

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us